ÂÜÀòÂÒÂ×

Neil Gallagher, M.D., Ph.D., has served as the President, Head of Research and Development since April 2023. Prior to joining Syndax, Dr. Gallagher served as Chief Medical Officer, Vice President, Head of Development at AbbVie from January 2020 to April 2023, where he led multiple development programs through approval globally and oversaw asset strategy and portfolio management across several therapeutic areas. Dr. Gallagher previously served as AbbVie’s Head of Global Oncology Development from November 2017 to December 2019. Prior to joining AbbVie, he served as Head of Development for Oncology and Inflammation at Amgen from May 2016 to October 2017 and spent a decade at Novartis leading several development and clinical programs across the portfolio. Earlier in his career, he was a Senior Medical Director at AstraZeneca and later Director of Clinical Development at Astex Therapeutics. Dr. Gallagher completed his Fellowship in Gynecological Oncology at the Institute for Cancer Studies, University of Birmingham, United Kingdom. Dr. Gallagher received his medical degree from Trinity College, Dublin.